Jordan M. Hyatt, Kathleen Powell, Nicolette K. Bell, K. B. Bucklen, D. Langleben
{"title":"Assessment of Attitudes Towards Medication-Assisted Drug Treatment Options among an Incarcerated Population","authors":"Jordan M. Hyatt, Kathleen Powell, Nicolette K. Bell, K. B. Bucklen, D. Langleben","doi":"10.1080/23774657.2021.1884032","DOIUrl":null,"url":null,"abstract":"ABSTRACT Medication-assisted treatment (MAT) is the state-of-the-art approach to treating opioid use disorder (OUD). Although OUD is prevalent among justice-involved populations, their attitudes toward MAT are largely unknown. Injectable extended release naltrexone (XR-NTX) is a MAT option, that is, unlike others, an opioid antagonist. We assess beliefs about XR-NTX as compared to methadone, a gold-standard pure opioid agonist MAT modality, in a sample of incarcerated men and women. Self-report data were collected from randomly selected adults (n = 1,570) residing in therapeutic communities (TCs) in 23 state correctional facilities. Distinct instruments addressed XR-NTX (n = 830) and methadone (n = 741). Prior knowledge and exposure to XR-NTX, and race, were significantly associated with positive beliefs about XR-NTX. Addiction history, race, beliefs about behavioral change, and a preference for injection over oral medications were positively associated with the average likelihood of opting for post-release XR-NTX treatment. Implications for health and correctional policy are discussed.","PeriodicalId":91861,"journal":{"name":"Corrections : policy, practice and research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23774657.2021.1884032","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Corrections : policy, practice and research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23774657.2021.1884032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
ABSTRACT Medication-assisted treatment (MAT) is the state-of-the-art approach to treating opioid use disorder (OUD). Although OUD is prevalent among justice-involved populations, their attitudes toward MAT are largely unknown. Injectable extended release naltrexone (XR-NTX) is a MAT option, that is, unlike others, an opioid antagonist. We assess beliefs about XR-NTX as compared to methadone, a gold-standard pure opioid agonist MAT modality, in a sample of incarcerated men and women. Self-report data were collected from randomly selected adults (n = 1,570) residing in therapeutic communities (TCs) in 23 state correctional facilities. Distinct instruments addressed XR-NTX (n = 830) and methadone (n = 741). Prior knowledge and exposure to XR-NTX, and race, were significantly associated with positive beliefs about XR-NTX. Addiction history, race, beliefs about behavioral change, and a preference for injection over oral medications were positively associated with the average likelihood of opting for post-release XR-NTX treatment. Implications for health and correctional policy are discussed.